Published in Cancer on March 19, 2014
Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging (2015) 0.87
Current status of radical prostatectomy for high-risk prostate cancer. Korean J Urol (2014) 0.83
Local treatment of high risk prostate cancer: Role of surgery and radiation therapy. Cancer (2014) 0.79
Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. BJU Int (2015) 0.78
Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer. Curr Urol (2016) 0.75
Integration and comparison of different genomic data for outcome prediction in cancer. BioData Min (2015) 0.75
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Early detection of prostate cancer: AUA Guideline. J Urol (2013) 9.14
Autonomic nerve development contributes to prostate cancer progression. Science (2013) 6.11
Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA (2008) 5.25
Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst (2009) 4.87
Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer (2008) 4.77
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Impact of age at diagnosis on prostate cancer treatment and survival. J Clin Oncol (2010) 2.89
Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol (2009) 2.88
Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer (2008) 2.83
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Androgen deprivation therapy and cardiovascular risk. J Clin Oncol (2011) 2.55
The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst (2008) 2.46
Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol (2013) 2.46
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Castration-resistant prostate cancer: AUA Guideline. J Urol (2013) 2.36
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol (2006) 2.31
The contemporary concept of significant versus insignificant prostate cancer. Eur Urol (2011) 2.29
Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev (2006) 2.28
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23
Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23
A simple schema for informed decision making about prostate cancer screening. Ann Intern Med (2014) 2.12
Prostate cancer in men using testosterone supplementation. J Urol (2005) 2.12
Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol (2011) 2.08
Association between exercise and primary incidence of prostate cancer: does race matter? Cancer (2013) 2.07
High-risk prostate cancer: from definition to contemporary management. Eur Urol (2012) 2.06
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol (2009) 1.97
Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol (2003) 1.93
The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology (2003) 1.84
The correlation between metabolic syndrome and prostatic diseases. Eur Urol (2011) 1.83
Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol (2012) 1.81
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology (2002) 1.81
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate (2012) 1.76
Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol (2009) 1.75